BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. Because a CpG island is found at the 5' end of the BRCA1 gene, we hypothesized that the decreased BRCA1 mRNA in sporadic breast cancer was associated with aberrant cytosine methylation of the CpG island. We examined BRCA1 mRNA expression in normal human mammary epithelial cells (HMECs), peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines using RT ± PCR. The normal breast cells expressed high levels of BRCA1 mRNA. The sporadic breast cancer cell lines and PBLs expressed lower levels of BRCA1 mRNA ranging from a 3 ± 16-fold decrease compared to the normal breast cells. We identi®ed a 600 bp region of the BRCA1 CpG island that possessed strong promoter activity (*40-fold above control), and determined the cytosine methylation patterns of the 30 CpG sites within this region by sodium bisul®te genomic sequencing. The HMECs, PBLs and ®ve of the sporadic breast cancer cell lines were largely unmethylated. However, one sporadic breast cancer cell line, UACC3199, was 560% methylated at all 30 CpG sites (18 sites were 100% methylated) and was associated with an eightfold decrease in BRCA1 mRNA compared to normal breast cells. These ®ndings suggest that aberrant cytosine methylation of the BRCA1 CpG island promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.
Introduction
Breast cancer is one of the most common cancers in the western world aecting one in ten women during their lifetime. The breast cancer susceptibility gene, BRCA1, was mapped to chromosome 17q21 by linkage studies (Hall et al., 1990) and later isolated by positional cloning . Since its cloning, germline mutations of BRCA1 have been found in the hereditary type of breast cancer (Friedman et al., 1994; Castilla et al., 1994) , however, no somatic mutations of BRCA1 have been found in the more common sporadic type of breast cancer Merajver et al., 1995) . Nevertheless, BRCA1 mRNA is reduced in invasive sporadic breast tumors despite the absence of mutations (Thompson et al., 1995) .
Analysis of the BRCA1 5' regulatory region indicates that it is a TATA-less promoter that ®ts the criteria of a CpG island (Gardiner-Garden and Frommer, 1987) : it is 1580 bp in length, has a 56% cytosine and guanine content, and has an observed/expected CpG frequency of 0.72. CpG island promoters can be repressed by aberrant cytosine methylation of the CpG dinucleotide; a common event in the progression of cancer (Issa et al., 1994; Belinsky et al., 1996; Rideout et al., 1994) . Other tumor suppressor genes that contain CpG island promoters in which aberrant methylation is associated with gene repression include Rb, p15, p16 and VHL (Greger et al., 1994; Herman et al., 1994 Herman et al., , 1996 Gonzalez-Zulueta et al., 1995) . Although two recent reports showed that aberrant methylation of the BRCA1 CpG island promoter occurred in two of seven and two of six sporadic breast cancer tumor samples, respectively (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) , these studies did not associate the aberrant methylation of the BRCA1 promoter with repression of the gene.
In this study we used sodium bisul®te genomic sequencing to analyse the cytosine methylation status of 30 CpG sites in a 600 bp promoter region of the BRCA1 gene and measured BRCA1 mRNA expression by RT ± PCR in normal human mammary epithelial cells (HMECs), normal peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines. BRCA1 mRNA expression was decreased 3 ± 16 fold in all six sporadic breast cancer cell lines when compared to the normal breast cells. Although ®ve of the sporadic breast cancer cell lines were unmethylated, one cell line, UACC3199, was 560% methylated at all 30 CpG sites (18 sites were 100% methylated) and was associated with an eightfold decrease in BRCA1 mRNA. These results suggest that aberrant cytosine methylation of the BRCA1 CpG island promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.
Results
Measurement of BRCA1 mRNA by RT ± PCR BRCA1 expression was measured by RT ± PCR in normal human mammary epithelial cells (HMECs), normal peripheral blood lymphocytes (PBLs) and the sporadic breast cancer cell lines MCF7, UACC893, UACC1179, UACC2087, UACC2648 and UACC3199 (Meltzer et al., 1991; Thompson et al., 1993; Guan et al., 1994) . BRCA1 mRNA levels were normalized to mRNA levels of histone 3.3 (H3.3), a cell-cycle independent, ubiquitously-expressed histone variant (Wells and Kedes, 1985) . The PCR conditions used to measure BRCA1 and H3.3 expression were in the linear range of ampli®cation (data not shown) assuring good estimates of gene expression. Figure 1 and Table 1 summarize the results of these experiments. The normal HMECs expressed the highest levels of BRCA1 mRNA. In comparison, all six sporadic breast cancer cell lines exhibited decreases in BRCA1 mRNA. MCF7 expressed threefold less, UACC2648 expressed fourfold less, UACC893 and UACC1179 expressed sixfold less, UACC3199 expressed eightfold less and UACC2087 expressed 16-fold less BRCA1 mRNA when compared to the normal HMECs. The normal PBLs, generally considered to be BRCA1 negative by Northern blot analysis , expressed low but detectable levels of BRCA1 mRNA; eightfold less than the normal HMECs. Two of the cell lines analysed, UACC2087 and UACC3199, expressed levels of BRCA1 mRNA as low as those found in PBLs.
5-methylcytosine analysis of a region of the BRCA1 CpG island containing strong promoter activity Four deletion constructs of the BRCA1 CpG island were cloned into the luciferase reporter vector pGL3-Basic and were labeled relative to the distance of the 5' end of the BRCA1 fragment from the exon 1a transcriptional start site. These deletion constructs were transiently transfected into the BRCA1 expressing MCF7 breast cancer cell line and the low BRCA1 expressing UACC3199 breast cancer cell line. The MCF7 and UACC3199 cells were co-transfected with the pRL-null reporter vector to normalize for transfection eciency. Figure 2 shows that the longest deletion constructs, 71460 and 7957, gave a 13-fold and 28-fold increase in promoter activity, respectively, compared to the promoterless control vector, pGL3-Basic, in the MCF7 cells. The 7567 construct exhibited a 440-fold increase in promoter activity. The strong promoter activity observed with the 7567 construct was abolished when the upstream region was deleted as illustrated by the +26 construct. These ®ndings are in agreement with a recent report that showed that the 7567 construct contains the maximal promoter of BRCA1 and that regions further upstream have decreased promoter activity suggesting the presence of negative regulatory elements (Xu et al., 1997b) . As shown in Figure 2 , all of the deletion constructs upstream of the transcriptional start site had high levels of promoter activity in the low BRCA1 expressing cell line UACC3199. The promoter activity was abolished inside of the transcriptional start site in these cells, similar to MCF7.
Sodium bisul®te genomic sequencing was used to assess the cytosine methylation status of 30 CpG dinucleotides in the BRCA1 5' region containing the highest promoter activity in the HMECs, PBLs and six sporadic breast cancer cell lines. Ten clones from each cell type were used to formulate a percent cytosine methylation for each CpG dinucleotide. As shown in Figure 3 , the high BRCA1 expressing normal HMECs were almost completely unmethylated in this promoter region except for one CpG dinucleotide at 755 being Figure 1 Analysis of BRCA1 mRNA expression by RT ± PCR. BRCA1 (top panel) and histone 3.3 (bottom panel) mRNA expression was determined by using 400 ng of RNA reverse transcribed from normal peripheral blood lymphocytes (lane 1), normal human mammary epithelial cells (lane 2), and six sporadic breast cancer cells: MCF7, UACC893, UACC1179, UACC2087, UACC2648 and UACC3199 (lanes 3 ± 8, respectively). Half of the RT reaction was used for PCR using BRCA1-speci®c primers located in exon 22 and exon 24 and the remaining half of the RT reaction was used for PCR using H3.3-speci®c primers. Each PCR reaction was optimized for 28 and 25 cycles, respectively, to ensure that ampli®cation was in the exponential range. Quantitative analysis was performed by measuring the density of BRCA1 mRNA expression as a function of the loading control histone 3.3 mRNA expression (BRCA1/H3.3). This experiment was performed twice with similar results Figure 1 and are relative to HMEC.
b Presence or absence of CpG methylation in the BRCA1 promoter region Figure 2 Identi®cation of a promoter region of BRCA1. 5' deletion constructs were created and labeled relative to the exon 1a transcription start site of BRCA1, as represented by the bent arrow, and inserted into the pGL3 vector containing the luciferase reporter gene. The deletion constructs were transiently transfected into the BRCA1 expressing MCF7 or the low BRCA1 expressing UACC3199 sporadic breast cancer cell lines and luciferase activity was assayed. Cells were co-transfected with the pRL-null reporter vector to normalize for transfection eciency. The data is presented as the average fold increase in promoter activity relative to the promoterless pGL3-Basic control 10% methylated. The BRCA1 negative PBLs were also largely unmethylated except for three CpGs at 7567, 7565 and 7189 that were 30%, 60% and 10% methylated, respectively. These results are consistent with current data indicating that CpG islands are unmethylated in all normal tissues regardless of expression status of the associated gene (Bird, 1986) . Five of the sporadic breast cancer cell lines were largely unmethylated except for 10 ± 30% methylation occurring at random CpG sites. However, the sporadic breast cancer cell line UACC3199 was 560% methylated at all 30 CpG sites and 18 of these sites were 100% methylated. The aberrant methylation of the UACC3199 BRCA1 CpG island promoter was associated with low BRCA1 expression, similar to the BRCA1 negative PBLs: an eightfold decrease in BRCA1 mRNA compared to normal breast cells. A summary of these ®ndings is reported in Table 1 .
Sodium bisul®te genomic sequencing was also used to assess the methylation status of the 6 CpG sites in the reported alternate reporter of BRCA1 in intron 1 (Xu et al., 1997b) . As shown in Figure 3 , these 6 CpGs were relatively unmethylated in all of the cell types, although UACC3199 had low levels of methylation (30%) at four of the CpG sites. Methylation of nonCpG cytosines was not observed in any of the samples analysed. It is noteworthy that a C?G polymorphism was detected at nt + 221 in PBLs, UACC1179, UACC2087 and UACC3199.
Discussion
The purpose of this study was to determine if decreased levels of BRCA1 mRNA in sporadic breast cancer is associated with the repressive eects of aberrant cytosine methylation in the BRCA1 CpG island promoter. We analysed levels of BRCA1 expression in normal human mammary epithelial cells (HMECs), normal peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines using RT ± PCR. All of the sporadic breast cancer cell lines had decreased levels of BRCA1 mRNA compared to the normal HMECs. Two sporadic breast cancer cell lines, UACC2087 and UACC3199, expressed 16-fold and eightfold less BRCA1 mRNA, respectively, compared to HMECs; levels of expression similar to the BRCA1 negative PBLs.
We identi®ed a strong promoter in the BRCA1 5' anking region by creating deletion constructs containing a luciferase reporter gene and transiently transfected the constructs into the BRCA1 expressing MCF7 Figure 3 Sodium bisul®te genomic sequencing of the BRCA1 promoter. (a) The 567 bp of the BRCA1 promoter region, exon 1a and intron 1 containing 36 CpGs was analysed for cytosine methylation. The bent arrow indicates the transcriptional start site of exon 1a with the numbering system based on the published sequence of the BRCA1 5' region (Xu et al., 1995) . (b) Bisul®te-modi®ed genomic DNA from normal peripheral blood lymphocytes (PBLs), normal human mammary epithelial cells (HMECs) and the six sporadic breast cancer cell lines were PCR ampli®ed, cloned and sequenced. Ten clones from each cell line were analysed to obtain percent methylation of the 36 CpG dinucleotides cell line and the low BRCA1 expressing UACC3199 cell line. In the MCF7 cells, a region 567 bp upstream of the exon 1a transcriptional start site of BRCA1 possessed a 440-fold increase in promoter activity compared to control. This strong promoter activity was eliminated inside of the transcriptional start site. The longer deletion constructs, 71460 and 7957, also possessed promoter activity with a 13-fold and a 28-fold increase over control, respectively. The decrease in promoter activity in the longer constructs suggests the presence of negative regulatory elements further upstream of the promoter region. These ®ndings are similar to a recent report by Xu et al. (1997b) .
The strong promoter region spanning 7567 to +44 of the BRCA1 CpG island and containing 30 CpG dinucleotides was analysed for the presence of 5-methylcytosine by sodium bisul®te genomic sequencing. The normal cells, the BRCA1 expressing HMECs and the BRCA1 negative PBLs, were largely unmethylated as predicted (Bird, 1986) . The MCF7, UACC893, UACC1179, UACC2087 and UACC2648 sporadic breast cancer cell lines were also unmethylated. However, UACC3199 was 560% methylated at all 30 CpG sites and 18 of these sites were 100% methylated. The aberrant methylation of the BRCA1 promoter in UACC3199 is associated with an eightfold decrease in BRCA1 expression; levels of expression similar to the BRCA1 negative PBLs. Despite the low levels of BRCA1 expression in UACC3199, transient transfections of this cell line with the BRCA1 deletion constructs show that these cells possess the necessary transcription factors to drive BRCA1 promoter activity. In addition, methylation of the BRCA1 CpG island promoter in UACC3199 is a selective event since the CpG islands of p15 and dCK remained unmethylated in these cells, similar to normal tissue (data not shown).
Our ®ndings that one of the six sporadic breast cancer cell lines examined was aberrantly methylated is comparable to two recent reports showing that two of seven and two of six sporadic breast tumor samples were aberrantly methylated (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) . In this study we show that the BRCA1 promoter region is methylated at every CpG dinucleotide with high frequency and is associated with a decrease in BRCA1 expression. Low levels of methylation of the reported alternate BRCA1 promoter and low levels of BRCA1 expression in UACC3199 suggest that this region may not be important in functional promoter activity. Taken together, these data suggest that aberrant methylation of the BRCA1 promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.
The 5-methylcytosine pattern observed in UACC3199 is similar to the pattern reported for Rb in retinoblastoma; extensive methylation of many contiguous CpG sites within a CpG island (Stirzaker et al., 1997) . This pattern of cytosine methylation is in contrast to instances where discrete regions (Watts et al., 1997; Pieper et al., 1996; Qian and Brent, 1997) or speci®c sites (Umezawa et al., 1997) of the cytosine methylation are associated with the transcriptional repression of genes. The methylation of discrete regions or speci®c sites is not likely to be relevant in the BRCA1 CpG island based on our study of the CpG island encompassing the 5' regulatory elements and intron 1.
Aberrant methylation of the BRCA1 promoter may also repress the expression of the newly discovered NBR2 gene (Xu et al., 1997a) . NBR2 lies 5300 bp upstream of exon 1a of BRCA1 and is transcribed in the reverse direction as BRCA1. The region between these genes is the BRCA1 maximal promoter that was analysed for 5-methylcytosine. The promoter is bidirectional for both BRCA1 and NBR2 but possesses twice as much promoter activity for NBR2 than BRCA1 (Xu et al., 1997b) . Therefore aberrant methylation of this promoter region may transcriptionally repress the NBR2 gene, similar to BRCA1. The consequences of decreased NBR2 expression is, as yet, unknown.
The ®ndings that the BRCA1 promoter is aberrantly methylated in sporadic breast cancer could have clinical as well as biological importance. Analysis of the BRCA1 promoter region for the presence of 5-methylcytosine could serve as a diagnostic or prognostic indicator for sporadic breast cancer. New therapeutic approaches using demethylating agents could be used in these cases to reactivate the BRCA1 gene. 5-azacytidine and 5-aza-2'-deoxycytidine have been shown to partially reverse the hypermethylation of other tumor suppressor genes resulting in reexpression of the gene (Herman et al., 1994 Otterson et al., 1995; Merlo et al., 1995) . Re-expression of BRCA1 by the demethylating agents could inhibit tumor growth by reactivation of BRCA1's tumor suppressor function.
Materials and methods

Cell culture
MCF7 cells were obtained from the American Type Culture Collection (Rockville, MD.) and cultured in RPMI 1640 supplemented with 5% fetal bovine serum (Tissue Culture Biologicals, Tulare, CA), penicillin (100 U/ ml) (Gibco ± BRL, Grand Island, NY) and 1% glutamine (Gibco ± BRL) in 95% air-5% CO 2 atmosphere at 378C. Normal human mammary epithelial cells (HMECs) were obtained from Clonetics (San Diego, CA) and grown according to the manufacturer's instructions. The early passage sporadic breast cancer cell lines were developed and maintained at the Arizona Cancer Center Cell Culture Core Facility. UACC893 was derived from a primary specimen, UACC3199 was derived from the axillary lymph nodes, UACC1179 and UACC2087 were derived from pleural eusions and UACC2648 was from a peritoneal uid (Meltzer et al., 1991; Thompson et al., 1993; Guan et al., 1994) . Pathological examination con®rmed that UACC893 and UACC3199 are in®ltrating ductal carcinomas and UACC1179, UACC2087 and UACC2648 are adenocarcinomas.
Reverse transcription-PCR (RT ± PCR) analysis of BRCA1 mRNA expression
Total cellular RNA was isolated using the Qiagen RNA/ DNA Midi kit (Chatsworth, CA) and quantitated by absorbance measurements at 260 nm. To measure BRCA1 expression, the exponential range of ampli®cation of the PCR reaction was determined for BRCA1 and the normalization control histone 3.3 (H3.3) which is a cell cycle independent, ubiquitously-expressed histone variant (data not shown) (Wells and Kedes, 1985) . It was determined that 28 cycles for BRCA1 and 25 cycles for H3.3 yielded products in the exponential range of ampli®cation using the following reaction: 400 ng of total cellular RNA was reverse transcribed by incubating a 20 ml reaction mixture containing 16PCR buer (10 mM Tris [pH 8.3] , 50 mM KCl, 1.5 mM MgCl 2 ), 1 mM each dATP, dCTP, dGTP and dTTP, 200 pmol random hexamer, 20 U RNasin and 200 U Superscript II reverse transcriptase (Gibco ± BRL) at 508C for 60 min. The reaction was stopped by incubation at 998C for 10 min. The BRCA1-speci®c PCR was performed by adding 10 ml of the RT reaction to 40 ml of ampli®cation reaction mix: 16PCR buer, 50 pmol of BRCA1-speci®c primers from exon 22 (nt 5453 to nt 5474) and exon 24 (nt 5595 to nt 5614) as derived from the BRCA1 cDNA sequence and 1.25 U of Taq DNA polymerase followed by incubation at 928C for 2 min; 28 cycles of 928C for 1 min, 578C for 30 s, 728C for 1 min; and a ®nal extension at 728C for 5 min followed by a quick chill to 48C. H3.3 expression from the same cDNA reaction was analysed with PCR parameters identical to BRCA1 except that 25 cycles of PCR were performed using H3.3-speci®c primers as previously described (Pieper et al., 1990) . For analysis, 20% of the respective PCR products were separated through a 3% agarose gel, visualized and quantitated by ethidium bromide staining using the densitometry analysis of the Eagle Eye II Still Video System (Stratagene, La Jolla, CA). BRCA1 mRNA was quantitated as a function of the loading control histone 3.3 mRNA (BRCA1/H3.3). This experiment was performed twice with similar results.
Construction and transfection of plasmids
A 1704 bp fragment of the BRCA1 gene containing the 5' anking region, exon 1a and part of intron 1 was isolated by PCR using oligonucleotides (nt 121 ± 140 and nt 1806 ± 1824) derived from the reported BRCA1 sequence (Genbank accession #U37574) (Xu et al., 1995) . The PCR product was cloned into the pCRII vector (Invitrogen, Carlsbad, CA) and its identity was con®rmed by DNA sequencing. Using this BRCA1 plasmid, the restriction enzymes KpnI + XhoI, NheI + XhoI, BssHII + XhoI and SstI + XhoI (Gibco ± BRL) were used to make the deletion constructs 71460, 7957, 7567 and +26, respectively, which were cloned into the compatible restriction sites of the pGL3-Basic luciferase reporter vector (Promega Madison, WI). Five micrograms of each BRCA1 deletion construct was transfected into MCF7 or UACC3199 cells using DOTAP according to the manufacturer's instructions (Boehringer-Mannheim, Indianapolis, IN). Cells were co-transfected with the pRL-null reporter vector (Promega) to normalize for transfection eciency. The cells were lysed and assayed for luciferase expression on a Monolight 2010 luminometer (Analytical Luminescence Laboratory) according to the Dual-Luciferase Reporter Assay System instructions (Promega). This experiment was performed four times in duplicate for MCF7 and once in duplicate for UACC3199.
Sodium bisul®te genomic sequencing of the BRCA1 promoter Genomic DNA was isolated using the Qiagen RNA/DNA Midi kit and quantitated spectrophotometrically. Five micrograms of genomic DNA was modi®ed with sodium bisul®te under the conditions described by Clark et al. (1994) . Brie¯y, DNA was denatured with 0.3 M NaOH, reacted with 3.6 M sodium bisul®te (pH 5) at 558C for 14 h, desalted by using a Wizard Prep kit (Promega), desulfonated with 0.3 M NaOH and ®nally ethanol precipitated in preparation for PCR. The BRCA1 promoter CpG island was ampli®ed from the bisul®te-modifed DNA by two rounds of PCR using nested primers speci®c to the bisul®te-modi®ed sequence of the BRCA1 CpG island. The primers are as follows: primer 1 (nt 895 to nt 916), 5'-GGGGTTGGATGGGAATTGTAG-3'; primer 2 (nt 1688 to nt 1792), 5'-CTCTACTACCTT-TACCCAAAAACA-3'; primer 3 (nt 989 to nt 1013), 5'-GTTTATAATTGTTGATAAGTATAAG-3'; primer 4 (nt 1626 to nt 1646), 5'-AAAACCCCACAACCTATCCC-3'. Primers 1 and 2 were used in the ®rst round of ampli®cation under the following conditions: 958C for 1 min followed by 35 cycles of 928C for 1 min, 568C for 3 min, 728C for 1 min; ending with a ®nal extension of 728C for 5 min and a quick chill to 48C. One to ten per cent of the ®rst round PCR product was used for the second round of PCR using primers 3 and 4 under the same conditions. The resultant PCR product was cloned into a TA vector according to the manufacturer's instructions (Original TA cloning kit [Invitrogen] and pGEM-T-Easy cloning kit [Promega] ). Ten positive recombinants were isolated using a Qiaprep Spin Plasmid Miniprep kit (Qiagen) according to the manufacturer's instructions and sequenced on an ABI automated DNA sequencer. The methylation status of individual CpG sites was determined by comparison of the sequence obtained with the known BRCA1 sequence. The number of methylated CpGs at a speci®c site was divided by the number of clones analysed (n=10 in all cases) to yield a percent methylation for each site. This method was also used to analyse methylation status of p15, dCK and the ®rst intron of BRCA1. The primer set for the BRCA1 intron are as follows: primer 1 (nt 1691 to nt 1713), 5' -T T TGGGTAAAGGTAGTAGAGT T T -3'; primer 2 (nt 2309 to nt 2331), 5'-TTAAATTCTCCCTCCCACAA-AAT-3'; primer 3 (nt 1724 to nt 1746), 5'-ATAGGG-GGTTTAAGTGATGTTTT-3'; primer 4 (nt 1842 to nt 1861), 5'-TACCCCCCTCCCCAAAATTC-3'.
Abbreviations HMEC, human mammary epithelial cells; PBL, peripheral blood lymphocytes; RT ± PCR, reverse transcription polymerase chain reaction; H3.3, histone 3.3; bp, base pair.
